Results 101 to 110 of about 683 (135)
Some of the next articles are maybe not open access.
Clinical Drug Investigation, 2012
Azilsartan medoxomil (Edarbi®; Ipreziv™) is an orally administered angiotensin II receptor type 1 antagonist (blocker) used in the treatment of adults with essential hypertension. This article reviews data on the clinical efficacy and tolerability of azilsartan medoxomil in adults with essential hypertension and provides a summary of its ...
Caroline M Perry, Perry Caroline M
exaly +3 more sources
Azilsartan medoxomil (Edarbi®; Ipreziv™) is an orally administered angiotensin II receptor type 1 antagonist (blocker) used in the treatment of adults with essential hypertension. This article reviews data on the clinical efficacy and tolerability of azilsartan medoxomil in adults with essential hypertension and provides a summary of its ...
Caroline M Perry, Perry Caroline M
exaly +3 more sources
Expert Opinion on Drug Metabolism and Toxicology, 2013
Azilsartan medoxomil is a newly approved angiotensin-receptor blocker for the management of hypertension. It is a prodrug that is quickly hydrolyzed to the active moiety azilsartan, a potent and highly selective angiotensin-receptor blocker with estimated bioavailability of ∼ 60%. This new agent induces a potent and long-lasting antihypertensive effect.
, , Fabio Angeli
exaly +5 more sources
Azilsartan medoxomil is a newly approved angiotensin-receptor blocker for the management of hypertension. It is a prodrug that is quickly hydrolyzed to the active moiety azilsartan, a potent and highly selective angiotensin-receptor blocker with estimated bioavailability of ∼ 60%. This new agent induces a potent and long-lasting antihypertensive effect.
, , Fabio Angeli
exaly +5 more sources
American Journal of Medicine, 2012
Chlorthalidone has proven efficacy to reduce cardiovascular morbidity and mortality, yet it is infrequently used in practice. This study provides a direct comparison of chlorthalidone with hydrochlorothiazide, each combined with the angiotensin receptor blocker azilsartan medoxomil, on blood pressure reduction and control rates.This is a randomized ...
William Cushman +2 more
exaly +3 more sources
Chlorthalidone has proven efficacy to reduce cardiovascular morbidity and mortality, yet it is infrequently used in practice. This study provides a direct comparison of chlorthalidone with hydrochlorothiazide, each combined with the angiotensin receptor blocker azilsartan medoxomil, on blood pressure reduction and control rates.This is a randomized ...
William Cushman +2 more
exaly +3 more sources
Efficacy of azilsartan medoxomil with chlorthalidone in hypertension
Expert Review of Cardiovascular Therapy, 2014Azilsartan medoxomil (AZL) is the most recently approved angiotensin receptor blocker (ARB) for treating patients with hypertension. A fixed-dose combination product with AZL and the thiazide-like diuretic chlorthalidone (CLD) is now available to treat individuals who require additional blood pressure lowering.
William L, Baker +2 more
openaire +2 more sources
Azilsartan Medoxomil Capabilities in Arterial Hypertension and Obesity
Kardiologiia, 2016Arterial hypertension (AH) is one of the most common cardiovascular disease. Angiotensin II (AT II), the hormone of renin-angiotensin-aldosterone system, realizes its negative effects through AT 1 receptors - application point of angiotensin receptor blockers (ARB).
Y A, Vasyuk +4 more
openaire +2 more sources
Azilsartan medoxomil, belimumab, and lurasidone hydrochloride
Journal of the American Pharmacists Association, 2011Antihypertensive agent Azilsartan medoxomil (Edarbi—Takeda) is the eighth angiotensin II receptor blocker (ARB) to be marketed in the United States, joining candesartan cilexetil (Atacand), eprosartan (Teveten), irbesartan (Avapro), losartan (e.g., Cozaar), olmesartan medoxomil (Benicar), telmisartan (Micardis), and valsartan (Diovan).
Daniel A. Hussar, Anokhi Shah
openaire +1 more source
Azilsartan medoxomil for the treatment of hypertension
Drugs of Today, 2011The use of angiotensin receptor blockers (ARBs) represents a favorable approach for the control of blood pressure in patients with hypertension. Azilsartan medoxomil, a prodrug that undergoes rapid hydrolysis to its active moiety azilsartan, is an angiotensin AT(1) receptor antagonist with promising antihypertensive activity and a good safety profile ...
openaire +2 more sources
Azilsartan Medoxomil/Chlorthalidone: A New Fixed-Dose Combination Antihypertensive
Annals of Pharmacotherapy, 2013OBJECTIVE To evaluate the efficacy, safety, and clinical utility of the combination product azilsartan medoxomil/chlorthalidone for the treatment of hypertension. DATA SOURCES Articles indexed in PubMed through December 2012 were ...
Danielle, Pierini +1 more
openaire +2 more sources
Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?
Expert Opinion on Pharmacotherapy, 2013Azilsartan medoxomil is the newest angiotensin receptor blocker marketed for the treatment of arterial hypertension. The aim of this article was to review the available evidence about this drug alone or combined with other antihypertensive agents in the treatment of hypertensive population.For this purpose, a search on MEDLINE and EMBASE databases was ...
Vivencio, Barrios, Carlos, Escobar
openaire +2 more sources
Improved Process for Azilsartan Medoxomil: A New Angiotensin Receptor Blocker
Organic Process Research & Development, 2012An improved process for the active pharmaceutical ingredient of a new angiotensin II AT1 receptor antagonist, azilsartan medoxomil, has been developed. The results include reinvestigation of the described process as well as its novel modifications. This new process includes transformation of the CN group into amidoxime moiety by aqueous hydroxylamine ...
Stanislav Rádl +3 more
openaire +1 more source